Compounds > arc 31
Page last updated: 2024-11-12

arc 31

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10070851
CHEMBL ID71086
SCHEMBL ID240616
MeSH IDM0524094

Synonyms (5)

Synonym
CHEMBL71086
arc-31
SCHEMBL240616
2,3-dimethoxy-11-[2-(dimethylamino)ethyl]-11,12-dihydro-8,9-(methylenedioxy)-5,6,11-triazachrysene-12-one
21-[2-(dimethylamino)ethyl]-16,17-dimethoxy-5,7-dioxa-11,12,21-triazapentacyclo[11.8.0.02,10.04,8.014,19]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 1Homo sapiens (human)IC10 (µMol)0.00030.00020.00030.0003AID362301
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID362301Inhibition of human topoisomerase 1 expressed in Escherichia coli assessed as YepG plasmid DNA cleavage2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
AID56881TOP-1 mediated DNA cleavage measured as effective concentration relative to topotecan = 12002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID331450Cytotoxicity against human RPMI-8240 cells2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Facile formation of hydrophilic derivatives of 5H-8,9-dimethoxy-5-[2-(N,N-dimethylamino)ethyl]-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one (ARC-111) and its 12-aza analog via quaternary ammonium intermediates.
AID110878In vivo antitumor activity in NCR-nude-nude mice inoculated with 1.2 E6 -1.5 E6 MDA-MB-435 cells; after day 13 with an average dose of 0.27 mg/mouse (po)2002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID331451Cytotoxicity against human camptothecin-resistant CPT-K5 cells2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Facile formation of hydrophilic derivatives of 5H-8,9-dimethoxy-5-[2-(N,N-dimethylamino)ethyl]-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one (ARC-111) and its 12-aza analog via quaternary ammonium intermediates.
AID362304Cytotoxicity against human KB3-1 cells after 4 days by MTT assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
AID110884In vivo antitumor activity in NCR-nude-nude mice inoculated with 1.2 E6 -1.5 E6 MDA-MB-435 cells; after day 31 with an average dose of 0.27 mg/mouse (po)2002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID331452Cytotoxicity against human P388 cells2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Facile formation of hydrophilic derivatives of 5H-8,9-dimethoxy-5-[2-(N,N-dimethylamino)ethyl]-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one (ARC-111) and its 12-aza analog via quaternary ammonium intermediates.
AID46871Cytotoxic activity against human lymphoblast tumor cell line CPT-K5 after 4 days of treatment2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity.
AID56880Effective concentration required to cleave DNA, mediated by human DNA topoisomerase I (TOP1) reported as REC i.e. concentration relative to topotecan (assumed as 1)2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity.
AID110886In vivo antitumor activity in NCR-nude-nude mice inoculated with 1.2 E6 -1.5 E6 MDA-MB-435 cells; after day 7 with an average dose of 0.22 mg/mouse (ip)2002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID331449Effect on human topoisomerase 1-mediated plasmid DNA cleavage relative to topotecan2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Facile formation of hydrophilic derivatives of 5H-8,9-dimethoxy-5-[2-(N,N-dimethylamino)ethyl]-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one (ARC-111) and its 12-aza analog via quaternary ammonium intermediates.
AID167217Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity.
AID362303Cytotoxicity against human camptothecin-resistant CPT-K5 cells after 4 days by MTT assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
AID46874Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-12002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID331453Cytotoxicity against human camptothecin-resistant P388/CPT45 cells2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Facile formation of hydrophilic derivatives of 5H-8,9-dimethoxy-5-[2-(N,N-dimethylamino)ethyl]-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one (ARC-111) and its 12-aza analog via quaternary ammonium intermediates.
AID362305Cytotoxicity against human multidrug resistant MDR1 overexpressing human KBV1 cells after 4 days by MTT assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
AID110887In vivo antitumor activity in NCR-nude-nude mice inoculated with 1.2 E6 -1.5 E6 MDA-MB-435 cells; after day 7 with an average dose of 0.27 mg/mouse (po)2002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID362300Cytotoxicity against mouse CPT45-resistant topoisomerase 1-deficient P388 cells after 4 days by MTT assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
AID110877In vivo antitumor activity in NCR-nude-nude mice inoculated with 1.2 E6 -1.5 E6 MDA-MB-435 cells; after day 13 with an average dose of 0.22 mg/mouse (ip)2002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID57214TOP-2 mediated DNA cleavage measured as effective concentration relative to VM262002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID362306Cytotoxicity against human multidrug resistant BCRP overexpressing human KBH5.0 cells after 4 days by MTT assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
AID362299Cytotoxicity against mouse P388 cells after 4 days by MTT assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
AID56879Concentration relative to topotecan for topoisomerase DNA topoisomerase I cleavage2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones and related compounds as TOP1-targeting agents: influence of structure on the ternary cleavable complex formation.
AID166892Cytotoxicity against human lymphoblast tumor cell line RPM184022002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID362302Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
AID110880In vivo antitumor activity in NCR-nude-nude mice inoculated with 1.2 E6 -1.5 E6 MDA-MB-435 cells; after day 21 with an average dose of 0.22 mg/mouse (ip)2002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID110883In vivo antitumor activity in NCR-nude-nude mice inoculated with 1.2 E6 -1.5 E6 MDA-MB-435 cells; after day 31 with an average dose of 0.22 mg/mouse (ip)2002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
AID110881In vivo antitumor activity in NCR-nude-nude mice inoculated with 1.2 E6 -1.5 E6 MDA-MB-435 cells; after day 21 with an average dose of 0.27 mg/mouse (po)2002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.27 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index38.58 (26.88)
Search Engine Supply Index3.42 (0.95)

This Compound (26.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.7230delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		2.4220pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
irinotecan
[no description available]		2.4320carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
teniposide
[no description available]		2.4220aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
arc111
topovale: topoisomerase I-targeting anticancer drug; structure in first source		3.1250
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Neoplasms
[description not available]		02.0110
Breast Cancer
[description not available]		02.0410
Benign Neoplasms
[description not available]		02.0410
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0410
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0410